Searched for
NOVARTIS DRL
Novartis exits India arm, ChrysCapital-led group buys 70.68% stake for ₹1,446 croreSwiss drugmaker Novartis AG is selling its 70.68% stake in its Indian unit for Rs 1,446 crore to a consortium led by ChrysCapital. This div...- Bain dials Dr Reddy's Laboratories to team up for joint Cipla bidPrivate equity firm Bain Capital has approached Indian pharmaceutical company Dr Reddy's Laboratories (DRL) to explore a joint bid for the ...
- Dr Reddy's inks exclusive sales pact with Novartis IndiaUnder the arrangement, Dr Reddy's will have exclusive rights to promote and distribute the well-established Voveran range, the Calcium rang...
- Novartis India enters distribution pact with DRL for top brands, to lay off 400 employeesNovartis India said its strategic business decision will lead to the separation of approximately 400 employees due to role redundancies.
- Sun Pharmaceutical, Dr Reddy's Labs, JB Pharmaceuticals, Torrent Pharma and Piramal Pharma eye Oaknet HealthcareAnother mid-sized pharma firm, La Renon, backed by Sequoia Capital and A91 Partners is also keen on buying out Oaknet. Binding bids will be...
- Goldman picks GRANOLAS in Europe. Does India have any for investors?What could a selection on similar lines look in case of India?
- Can Glenmark Pharma taste success where its peers have not?Glenmark's current innovation pipeline consists of eight assets.
- As going gets tough, pharma firms revisit past decisionsCompanies have rationalised field force and restructured product portfolio to up productivity.
- Dr Reddy's acquires Habitrol brandDr Reddy's Laboratories has acquired Habitrol brand, a nicotine replacement therapy transdermal patch, from Novartis Consumer Health Inc.
- Dr Reddy's Laboratories reports 17% net profit drop in July-September quarter, spent 12% of revenues on R&DDr Reddy's stock slipped 1.11% to close at Rs 3,046 on the Bombay Stock Exchange on Wednesday as the results fell short of street expectati...
- Dr Reddy's second quarter net down 17 per cent at Rs 574.1 croreThe company reported sales of Rs 3,587 crore in the second quarter, 7% more than a year earlier, while net profit slipped 17% to Rs 574 cro...
- Some pharma stocks run out of steam; high valuations, regulatory issues lead to selloff pressure on StreetPharma stocks have become laggards of late, given their high valuations, regulatory issues and overall slowdown in sales.
- Pharma stocks rally after SC's Novartis verdict; analysts positive on DRL, Cipla, NatcoPharma stocks surged 2-5 per cent after the Supreme Court dismissed Novartis AG's plea for getting its blood cancer drug patented in India.
- We will cut drug prices by reducing production costs: GlaxoSmithklineThe world’s second-largest drugmaker GlaxoSmithkline (GSK) will bring down drug prices in India as part of a new strategy to tap lower-inco...
- Dr Reddy's in talks with Glaxo for stake saleMost MNCs are focusing on India and emerging markets to sustain their growth as the US and Europe markets slow down.
- DRL, Ranbaxy, Wockhardt vie for German mega-dealThe bid is scheduled to open in the first week of November. Germany, which is the world’s second largest drug market, looks for ways to cur...
- Indian generic companies may tread Ranbaxy pathRanbaxy's patent settlement with Pfizer may lead more Indian generic cos to go for out-of-court settlements with their innovator counterpar...
- DRL, Novartis smoke peace pipe on Alzheimer's drugDr Reddy’s Laboratories (DRL) has entered a settlement agreement with Novartis Pharma to suspend the launch of its generic capsule rivastig...
- Copycat drug cos convert, back MNCs on patentsOnce known for trashing patents and denouncing prohibitive pricing by big pharma, Indian generic companies have changed their stance.
- Cipla movement under Sebi lensTHE SECURITIES and Exchange Board of India has initiated a probe into the price movement of pharma major Cipla prior to its inclusion in th...
Load More
